Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US
Shots:
- Therapeutics MD to receive $15.82M upfront- $33.34M milestones including $2.26M as regulatory milestones & $31.08M as commercial milestones and royalties on sales in licensed territories
- Theramex to get exclusive commercialization rights for Bijuva and Imvexxy outside the US and is responsible for all regulatory and commercial activities in the licensed territories. Additionally- Therapeutics MD has licensed Bijuva and Imvexxy to Knight Therapeutics in Canada & Israel
- Bijuva is a bio-identical hormone therapy combination of estrogen and progesterone indicated for moderate to severe vasomotor symptoms. IMVEXXY is a vaginal estrogen therapy indicated to treat painful sexual activity
Ref: Therapeutics MD| Image: Theramex
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
